Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
Nigel J. Temperton* , Paul K. Chan†, Graham Simmons‡, Maria C. Zambon§, Richard S. Tedder*, Yasuhiro Takeuchi*, and Robin A. Weiss*
Author affiliations: *University College London, London, United Kingdom; †Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, People’s Republic of China; ‡University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; §Health Protection Agency Central Public Health Laboratory, London, United Kingdom
Figure 4. . Neutralizing antibodies to severe acute respiratory syndrome–associated coronavirus spike protein in sequential blood samples from 4 representative patients. Lines represent profiles of individual patients. Filled black symbols represent geometric mean titers at individual time points. IC90, 90% inhibitory concentration.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.